Tarceva maintenance indication in lung cancer faces three-month US delay
This article was originally published in Scrip
Executive Summary
The US FDA has extended its review of the supplemental application for Genentech's (Roche) and OSI Pharmaceuticals' EGFR-targeted anticancer Tarceva (erlotinib) for use as a first-line maintenance therapy in advanced non-small cell lung cancer (NSCLC), following OSI's submission of further data in support of the application.